Loading...
Fetching results...
0 items found

465: Young men with low risk prostate cancer can be safely candidate to active surveillance regardless of the extent of biopsy involvement: Results from a single center series with pathological confirmation

Speaker
L. Nocera, Milano (IT)
Authors
Bandini M. 1 , Scarcella S. 2 , Suardi N. 1 , Nocera L. 1 , Gandaglia G. 1 , Fossati N. 1 , Stabile A. 1 , Dell'Oglio P. 1 , Shariat S. 3 , Longo N. 4 , Mirone V. 4 , Scuderi S. 1 , Karakiewicz P. 5 , Robesti D. 1 , Rizzo A. 1 , Cannoletta D. 1 , Barletta F. 1 , Pellegrino A. 1 , Montorsi F. 1 , Briganti A. 1
Institutions
1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3Vienna General Hospital, Dept. of Urology, Vienna, Austria, 4University of Naples Federico II, Dept. of Urology, Naples, Italy, 5University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 6
Event
34th Annual EAU Congress (EAU19)
Date – Time - Location
17 March 2019, 12:15 - 13:45, Green Area, Room 2
Session
Poster Session 33 - Active surveillance versus focal therapy in prostate cancer?
Topic
Prostate cancer: Treatment: Active surveillance, focal, and ablative therapies
  • © 2021 European Association of Urology
  • Disclaimer